Febrile Neutropaenia

  • N. V. Maheshwari


  • Febrile neutropaenia (FN) should be suspected in all immune-compromised patients who present to the emergency department (ED) with fever and neutropaenia.

  • FN is a time-dependent life-threatening condition.

  • The following features clearly have an impact on the high morbidity and mortality:
    • Prompt recognition in patients who have recently received chemotherapy

    • Investigation for a potential infective source

    • Initiation of empirical broad-spectrum antimicrobial based on local microbial aetiology


Severe Sepsis Infective Endocarditis Absolute Neutrophil Count Clinical Pathway Microbial Aetiology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Tattersall M. Febrile neutropenia: a necessary evil? Int J Antimicrob Agents. 2000;16(2):85–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Tormay C. Febrile neutropenia. Aust Emerg Nurs J. 1997;1(3):30–2.CrossRefGoogle Scholar
  3. 3.
    de Naurois J, Novitzky-Basso I, Gill M, Marti F, Cullen M, Roila F. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010;21(Supplement 5):v252–6.CrossRefPubMedGoogle Scholar
  4. 4.
    BMJ Practice. Febrile neutropenia [Internet]. BMJ. [cited 1 March 2015]. Available from:
  5. 5.
    Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. 2013;19(5):474–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Ellis M. Febrile neutropenia. Ann N Y Acad Sci. 2008;1138(1):329–50.CrossRefPubMedGoogle Scholar
  7. 7.
    Lyman G, Kuderer N. Moving beyond febrile neutropenia. Support Cancer Ther. 2005;2(2):95–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Lyman G, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol. 2014;90(3):190–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Dellinger R, Levy M, Rhodes A, Annane D, Gerlach H, Opal S, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228.CrossRefPubMedGoogle Scholar
  10. 10.
    Bow E, Wingard J. Overview of neutropenic fever syndromes [Internet] [cited 17 Mar 2015]. Available from:
  11. 11.
    Oberoi S, Trehan A, Marwaha R, Bansal D. Symptom to door interval in febrile neutropenia: perspective in India. Support Care Cancer. 2012;21(5):1321–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.Pathology, Faculty of Health Sciences & MedicineBond UniversityGold CoastAustralia

Personalised recommendations